Orthofix Medical (NASDAQ:OFIX - Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Orthofix Medical has set its FY 2024 guidance at EPS.Individual that wish to listen to the company's earnings conference call can do so using this link.
Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.58). The firm had revenue of $198.62 million for the quarter, compared to analyst estimates of $195.75 million. Orthofix Medical had a negative return on equity of 20.68% and a negative net margin of 15.61%. On average, analysts expect Orthofix Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Orthofix Medical Stock Performance
Shares of NASDAQ OFIX traded down $0.16 during trading hours on Thursday, reaching $16.19. The stock had a trading volume of 217,448 shares, compared to its average volume of 323,822. Orthofix Medical has a twelve month low of $9.57 and a twelve month high of $17.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.48 and a quick ratio of 1.13. The business's fifty day moving average is $16.17 and its two-hundred day moving average is $15.06. The company has a market cap of $618.05 million, a price-to-earnings ratio of -5.03 and a beta of 1.05.
About Orthofix Medical
(
Get Free Report)
Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
See Also
Before you consider Orthofix Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orthofix Medical wasn't on the list.
While Orthofix Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
